Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line immunotherapy in non-small cell lung cancer: how to select and where to go.
Mogavero A, Cantale O, Mollica V, Anpalakhan S, Addeo A, Mountzios G, Friedlaender A, Kanesvaran R, Novello S, Banna GL. Mogavero A, et al. Among authors: mollica v. Expert Rev Respir Med. 2023 Dec;17(12):1191-1206. doi: 10.1080/17476348.2024.2302356. Epub 2024 Feb 9. Expert Rev Respir Med. 2023. PMID: 38294292 Review.
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study.
Bersanelli M, Buti S, Banna GL, De Giorgi U, Cortellini A, Rebuzzi SE, Tiseo M, Fornarini G, Mazzoni F, Panni S, De Tursi M, Di Marino P, Rossetti S, Rossi E, Tomao S, De Luca E, Sorarù M, Mucciarini C, Atzori F, La Torre L, Vitale MG, Martelli V, Sepe P, Mollica V, Vaccaro V, Schinzari G, Ficorella C, Massari F, Maestri A, Sabbatini R, Sava T, Di Maio M, Verzoni E, Procopio G, Giannarelli D. Bersanelli M, et al. Among authors: mollica v. Immunotherapy. 2020 Feb;12(2):151-159. doi: 10.2217/imt-2019-0180. Immunotherapy. 2020. PMID: 32089035
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Rebuzzi SE, Signori A, Banna GL, Maruzzo M, De Giorgi U, Pedrazzoli P, Sbrana A, Zucali PA, Masini C, Naglieri E, Procopio G, Merler S, Tomasello L, Fratino L, Baldessari C, Ricotta R, Panni S, Mollica V, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Stellato M, Atzori F, Pignata S, Messina C, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Pierantoni F, Casadei C, Bersanelli M, Chiellino S, Paolieri F, Perrino M, Brunelli M, Iacovelli R, Porta C, Buti S, Fornarini G. Rebuzzi SE, et al. Among authors: mollica v. Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34046089 Free PMC article.
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna GL, Fornarini G. Rebuzzi SE, et al. Among authors: mollica v. Cancers (Basel). 2022 Feb 28;14(5):1245. doi: 10.3390/cancers14051245. Cancers (Basel). 2022. PMID: 35267553 Free PMC article. Review.
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
Rebuzzi SE, Signori A, Banna GL, Gandini A, Fornarini G, Damassi A, Maruzzo M, De Giorgi U, Basso U, Chiellino S, Galli L, Zucali PA, Fantinel E, Naglieri E, Procopio G, Milella M, Boccardo F, Fratino L, Pipitone S, Ricotta R, Panni S, Mollica V, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Santini D, Atzori F, Di Napoli M, Caffo O, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Rescigno P, Buti S. Rebuzzi SE, et al. Among authors: mollica v. J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6. J Transl Med. 2022. PMID: 36180954 Free PMC article.
Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer.
Banna GL, Friedlaender A, Tagliamento M, Mollica V, Cortellini A, Rebuzzi SE, Prelaj A, Naqash AR, Auclin E, Garetto L, Mezquita L, Addeo A. Banna GL, et al. Among authors: mollica v. Curr Oncol Rep. 2022 Dec;24(12):1851-1862. doi: 10.1007/s11912-022-01335-8. Epub 2022 Oct 18. Curr Oncol Rep. 2022. PMID: 36255605 Review.
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, Kopecky J, Kucharz J, Buti S, Salfi A, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Zakopoulou R, Caffo O, Procopio G, Bassanelli M, Zampiva I, Messina C, Küronya Z, Mosca A, Bhuva D, Vau N, Incorvaia L, Rebuzzi SE, Roviello G, Zabalza IO, Rizzo A, Mollica V, Catalini I, Monteiro FSM, Montironi R, Battelli N, Rizzo M, Porta C. Santoni M, et al. Among authors: mollica v. Clin Genitourin Cancer. 2023 Oct;21(5):e309-e319.e1. doi: 10.1016/j.clgc.2023.03.006. Epub 2023 Mar 20. Clin Genitourin Cancer. 2023. PMID: 37062658
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Santoni M, et al. Among authors: mollica v. Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21. Eur Urol Oncol. 2024. PMID: 37481365
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.
Catalano M, Rebuzzi SE, Maruzzo M, De Giorgi U, Buti S, Galli L, Fornarini G, Zucali PA, Procopio G, Chiellino S, Milella M, Catalano F, Pipitone S, Ricotta R, Sorarù M, Mollica V, Tudini M, Fratino L, Prati V, Caffo O, Atzori F, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Di Napoli M, Malgeri A, Naglieri E, Signori A, Banna GL, Rescigno P, Antonuzzo L, Roviello G. Catalano M, et al. Among authors: mollica v. JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185. JAMA Netw Open. 2023. PMID: 38010650 Free PMC article.
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, Silini EM, Quaini F, De Filippo M, Brunelli M, Banna GL, Rescigno P, Signori A, Buti S. Maffezzoli M, et al. Among authors: mollica v. Clin Exp Metastasis. 2024 Apr;41(2):117-129. doi: 10.1007/s10585-024-10266-6. Epub 2024 Feb 16. Clin Exp Metastasis. 2024. PMID: 38363410 Free PMC article.
205 results